News summary COVID-19 Long haulers study to create personalized health risk scores and drug treatment recommendations based on patients' unique medical history and genetics AI-driven research and digital twins will support hospitals and research centers globally and contribute to Dell's goal to use technology and scale to advance health, education and economic opportunity for 1 billion people by 2030 Full story Dell Technologies (NYSE:DELL) is helping i2b2 tranSMART Foundation, a non-profit open-source research organization, mobilize huge amounts of global de-identified patient data to create virtual models of patients – known as digital twins – to treat impacts of long-haul COVID-19. Through Dell Technologies' modern infrastructure, the i2b2 tranSMART community will use de-identified patient data to produce digital twins. Researchers can then perform millions of individualized treatment simulations on the digital twins to determine the best possible therapy option for patients, based on genetic background and medical history.